[Thoughts on autologous hematopoietic stem cell transplantation and mobilization in Chinese patients with non Hodgkin's lymphoma].
作者信息
Zhu J
机构信息
Department of Lymphoma, Peking University Cancer Hospital, Beijing Institute for Cancer Research, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2020 Jan 14;41(1):1-4. doi: 10.3760/cma.j.issn.0253-2727.2020.01.001.
Abstract
摘要
相似文献
1
[Thoughts on autologous hematopoietic stem cell transplantation and mobilization in Chinese patients with non Hodgkin's lymphoma].[关于中国非霍奇金淋巴瘤患者自体造血干细胞移植及动员的思考]
Zhonghua Xue Ye Xue Za Zhi. 2020 Jan 14;41(1):1-4. doi: 10.3760/cma.j.issn.0253-2727.2020.01.001.
2
Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.培洛昔福联合粒细胞集落刺激因子在淋巴瘤和多发性骨髓瘤一线稳定期自体外周血造血干细胞动员中的应用：前瞻性 PREDICT 试验结果。
Haematologica. 2013 Feb;98(2):172-8. doi: 10.3324/haematol.2012.071456. Epub 2012 Sep 14.
3
Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.一项III期前瞻性随机双盲安慰剂对照试验，比较普乐沙福加粒细胞集落刺激因子与安慰剂加粒细胞集落刺激因子用于非霍奇金淋巴瘤患者自体干细胞动员和移植的效果
J Clin Oncol. 2009 Oct 1;27(28):4767-73. doi: 10.1200/JCO.2008.20.7209. Epub 2009 Aug 31.
4
Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.普乐沙福与粒细胞集落刺激因子用于动员中国非霍奇金淋巴瘤患者造血干细胞以进行自体移植：一项随机3期研究
Transfusion. 2018 Jan;58(1):81-87. doi: 10.1111/trf.14426. Epub 2017 Dec 13.
5
6
7
High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.使用未预激和粒细胞集落刺激因子动员的外周血干细胞，对霍奇金病和非霍奇金淋巴瘤患者进行大剂量治疗后自体外周血干细胞移植。
J Clin Oncol. 1994 Oct;12(10):2176-86. doi: 10.1200/JCO.1994.12.10.2176.
8
9
Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.普乐沙福：一种趋化因子受体-4 拮抗剂，用于高剂量化疗治疗非霍奇金淋巴瘤或多发性骨髓瘤后移植造血干细胞的动员。
Clin Ther. 2010 May;32(5):821-43. doi: 10.1016/j.clinthera.2010.05.007.
10
The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation.地塞米松、阿糖胞苷和顺铂（DHAP）方案对适合 upfront 自体干细胞移植的非霍奇金淋巴瘤患者干细胞动员和移植结局的影响。
Korean J Intern Med. 2018 Nov;33(6):1169-1181. doi: 10.3904/kjim.2016.163. Epub 2018 Jan 8.
引用本文的文献
1
Fate of hematopoietic stem cells determined by Notch1 signaling (Review).Notch1信号通路决定造血干细胞的命运（综述）
Exp Ther Med. 2022 Feb;23(2):170. doi: 10.3892/etm.2021.11093. Epub 2021 Dec 27.
本文引用的文献
1
[Report of cancer epidemiology in China, 2015].《2015年中国癌症流行病学报告》
Zhonghua Zhong Liu Za Zhi. 2019 Jan 23;41(1):19-28. doi: 10.3760/cma.j.issn.0253-3766.2019.01.005.
2
Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries.2003-2015 年期间中国癌症生存率变化：基于 17 个癌症登记处的汇总分析。
Lancet Glob Health. 2018 May;6(5):e555-e567. doi: 10.1016/S2214-109X(18)30127-X.
3
Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.普乐沙福与粒细胞集落刺激因子用于动员中国非霍奇金淋巴瘤患者造血干细胞以进行自体移植：一项随机3期研究
Transfusion. 2018 Jan;58(1):81-87. doi: 10.1111/trf.14426. Epub 2017 Dec 13.
4
Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.外周血干细胞动员不佳会影响接受自体干细胞移植的多发性骨髓瘤患者的长期预后。
J Clin Apher. 2018 Feb;33(1):29-37. doi: 10.1002/jca.21556. Epub 2017 May 29.
5
A review of hematopoietic cell transplantation in China: data and trends during 2008-2016.中国造血细胞移植回顾：2008-2016 年的数据和趋势。
Bone Marrow Transplant. 2017 Nov;52(11):1512-1518. doi: 10.1038/bmt.2017.59. Epub 2017 Apr 24.
6
Non-Hodgkin lymphoma.非霍奇金淋巴瘤。
Lancet. 2017 Jul 15;390(10091):298-310. doi: 10.1016/S0140-6736(16)32407-2. Epub 2017 Jan 31.
7
New agents in HSC mobilization.造血干细胞动员的新药物
Int J Hematol. 2017 Feb;105(2):141-152. doi: 10.1007/s12185-016-2156-2. Epub 2016 Nov 30.
8
Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor.优化难动员患者的动员策略：普乐沙福的作用。
Transfus Apher Sci. 2015 Aug;53(1):23-9. doi: 10.1016/j.transci.2015.05.011. Epub 2015 Jun 9.
9
Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.弥漫性大B细胞淋巴瘤一线含利妥昔单抗的化疗免疫疗法早期失败并不能预测自体造血细胞移植无效。
Biol Blood Marrow Transplant. 2014 Nov;20(11):1729-36. doi: 10.1016/j.bbmt.2014.06.036. Epub 2014 Jul 5.
10
Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation.用于自体和异基因造血细胞移植的外周血祖细胞动员：美国血液和骨髓移植学会指南
Biol Blood Marrow Transplant. 2014 Sep;20(9):1262-73. doi: 10.1016/j.bbmt.2014.05.003. Epub 2014 May 9.
Zotero 插件